ESR1 and breast carcinoma: Data also suggest that loss of E-cadherin expression may be associated with malignant progression, metastasis, and reduced survival in breast cancer patients24–28; however, most of these studies were based on small numbers and not all analyses were stratified by ER-status, a known important prognostic and predictive marker.